CORT CORCEPT THERAPEUTICS INC

NEUTRAL Impact: 3/10 Insider Cluster (2 insiders)
Horizon days Filed May 1, 2026 Processed 1mo ago
Insider cluster: 2 insiders, $3.0M total
Latest settled — T+20d
CORT ▲ +36.99% at T+20d
NEUTRAL call ✓ call won +36.99% · α vs SPY +31.70% · entry $51.42 → $70.44
Next anchor: T+60d in 6w
Currently $82.91 · +61.24% from $51.42 entry
Entry anchored
Apr 30, 03:59 PM ET
via Databento tick
T+1d
+0.35%
call +0.35% · α +0.69%
$51.60
settled 6w ago
T+5d
-0.72%
call -0.72% · α -3.07%
$51.05
settled 5w ago
T+20d
+36.99%
call +36.99% · α +31.70%
$70.44
settled 15d ago
T+60d
call — · α —
in 6w

Price Chart

Loading chart...

Executive Summary

Corcept Therapeutics' CEO and CDO sold $3.04M in open-market shares within a week of the Q1 earnings release. The trades represent only ~0.05% of market cap and are likely routine portfolio management, not a bearish signal. Q1 revenue grew 4.9% YoY to $164.9M, but the company reported a net loss of $31.8M vs net income of $20.5M in the prior year, driven by increased spending on the Lifyorli launch.

Key Financial Metrics

Direction
selling
Total Value
$3.0M
Insiders
2

Actionable Insight

Monitor upcoming Q2 earnings for profitability recovery as guided, and track early Lifyorli sales trajectory. Insider sales are minor and do not warrant action, but any acceleration in selling by C-suite would be a watch item.

Key Facts

  • CEO Belanoff sold 40,000 shares at ~$50.10 for $2.00M on May 1, 2026.
  • CDO Guyer sold 20,000 shares at ~$51.83 for $1.04M on May 5, 2026 (also exercised options with no cash impact).
  • Total insider sales of $3.04M represent ~0.054% of $5.6B market cap.
  • Q1 2026 revenue rose 4.9% YoY to $164.9M; net loss of $31.8M vs net income of $20.5M in Q1 2025.
  • 2026 revenue guidance raised to $950M-$1,050M; Lifyorli (relacorilant) approved by FDA for ovarian cancer in March 2026.

Financial Impact

Insider selling of $3.04M is negligible relative to $5.6B market cap.

revenuenet incomecash and investments

Risk Factors

  • Delays in relacorilant NDA for Cushing's syndrome or regulatory setbacks.
  • Competition in ovarian cancer and Cushing's syndrome markets.
  • Failure to return to profitability as guided in Q2 2026.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
75% bullish (12 analysts)

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-CORT-1778185862573
12 reports for CORT
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+60▲ +63.06%Feb 24, 2026
Filters
Rows
Reports for CORT — sortable, filterable
Type Now
Jun 4, 2026
8d ago
Insider Cluster
NEUTRAL ★ 3/10
$74.77 awaiting T+1awaiting T+1$82.91 (+10.89%)
Jun 3, 2026
9d ago
Insider Cluster
NEUTRAL ★ 3/10
$74.89 $72.62▼ −3.03%▼ −0.43%$82.91 (+10.71%)
Jun 3, 2026
9d ago
Insider Cluster
BEARISH ★ 5/10
$74.89 $72.62▲ +3.03%▲ +0.43%$82.91 (−10.71%)
Jun 3, 2026
9d ago
Insider Cluster
NEUTRAL ★ 4/10
$74.89 $72.62▼ −3.03%▼ −0.43%$82.91 (+10.71%)
Jun 3, 2026
9d ago
8-K
BULLISH ★ 6/10
$72.65 $74.89▲ +3.08%▲ +2.68%$82.91 (+14.12%)
Jun 2, 2026
10d ago
Insider Cluster
NEUTRAL ★ 3/10
$72.65 $74.89▲ +3.08%▲ +2.68%$82.91 (+14.12%)
May 29, 2026
14d ago
Insider Cluster
NEUTRAL ★ 3/10
$70.44 $71.20▲ +1.08%▲ +0.93%$82.91 (+17.70%)
May 29, 2026
14d ago
Insider Cluster
NEUTRAL ★ 3/10
$70.44 $71.20▲ +1.08%▲ +0.93%$82.91 (+17.70%)
May 1, 2026
6w ago
Insider Cluster
NEUTRAL ★ 3/10
$51.42 $51.60▲ +0.35%▲ +0.69%$82.91 (+61.24%)
Mar 20, 2026
12w ago
Insider Cluster
NEUTRAL ★ 3/10
$34.64 $33.63▼ −2.92%▼ −4.02%$82.91 (+139.35%)
Showing 10 of 12

US Market Status

Market Closed — Opens Mon (49h 31m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access